$77.59
+1.6%Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Chief Executive Officer & Director
Compensation
$4,456,913
Executive Vice President & Chief Commercial Officer
Compensation
$1,809,996
Executive Vice President & Chief Digital and Technology Officer
Executive Vice President & Chief Financial Officer
Compensation
$1,902,146
Executive Vice President and President of Global Manufacturing & Supply
Executive Vice President and President of Research & Development
Compensation
$1,523,134
Executive Vice President of Corporate Affairs & Chief Sustainability Officer
Executive Vice President, Chief Human Resources Officer & Global Operations
Executive Vice President, General Counsel & Corporate Secretary
Compensation
$1,365,476
Vice President of Investor Relations
During the last 12 months, insiders have purchased $886K and sold $1.16M worth of ZTS shares, resulting in $277K of net selling activity.
11.7K
886.37K
0
0.00
+886K
+$886K
0
0.00
9.2K
1.16M
-1.2M
-$1.16M
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
Damelio Frank A
Director
$501K
Mccallister Michael B
Director
$233K
Bisaro Paul
Director
$152K
Peck Kristin C
Director, Officer: Chief Executive Officer
$1.16M
Slightly bearish with $277K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
3 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
ZTS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 08, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 09, 2025 | May 21, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 10, 2024 | May 22, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 06, 2023 | April 06, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 06, 2022 | May 19, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 06, 2021 | May 20, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 06, 2020 | May 20, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 02, 2019 | May 15, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 02, 2018 | May 15, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 31, 2017 | May 11, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.